Gain Therapeutics Unveils Preclinical Data Showing GT-02287 Boosts Mitochondrial Function in Parkinson’s Models
Gain Therapeutics Inc. presented preclinical data on GT-02287 at Neuroscience 2025, showing its potential as a disease-modifying therapy for Parkinson’s. The drug enhances mitochondrial function by facilitating glucocerebrosidase trafficking, reducing mitochondrial stress, and improving neuronal survival in Parkinson’s models. These findings suggest GT-02287 could improve mitochondrial health in patients with GBA1 mutations. The data was shared at the Society for Neuroscience annual meeting in San Diego.
Gain Therapeutics Inc. announced new preclinical data on its lead drug candidate, GT-02287, at the Society for Neuroscience annual meeting, Neuroscience 2025, held November 15-19 in San Diego, CA. The results, presented in a poster session, demonstrated GT-02287’s mechanism of action in facilitating the trafficking of glucocerebrosidase (GCase) to mitochondria and lysosomes. The data showed that GT-02287 reduced mitochondrial stress, enhanced neuronal survival in rat dopaminergic neurons, and decreased MIRO1 staining in a mouse model of Parkinson’s disease, suggesting improved mitochondrial health. Additionally, the compound improved mitochondrial function in patient-derived fibroblasts with GBA1 mutations. The findings support GT-02287’s potential as a disease-modifying therapy for Parkinson’s disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9579463-en) on November 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
